High Level Antibody Avidity is Achieved in HIV-Seropositive Recipients of an Inactivated Split Adjuvanted (AS03A) Influenza Vaccine

Karen K. Yam; Erica Gipson; Marina Klein; Sharon Walmsley; David Haase; Scott Halperin; David Scheifele; Brian J. Ward; Curtis Cooper

doi:10.1007/s10875-014-0054-z

High Level Antibody Avidity is Achieved in HIV-Seropositive Recipients of an Inactivated Split Adjuvanted (AS03_A) Influenza Vaccine

Karen K. Yam, Erica Gipson, Marina Klein, Sharon Walmsley, David Haase, Scott Halperin, David Scheifele, Brian J. Ward, Curtis Cooper

Economics, Econometrics and Finance

Research output: Contribution to journal › Article › peer-review

7 Citations (Scopus)

Original language	English
Pages (from-to)	655-662
Number of pages	8
Journal	Journal of Clinical Immunology
Volume	34
Issue number	6
DOIs	https://doi.org/10.1007/s10875-014-0054-z
Publication status	Published - Aug 1 2014

ASJC Scopus Subject Areas

Immunology and Allergy
Immunology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1007/s10875-014-0054-z

Cite this

@article{c9e3f80662d147d1b120047e3a21818d,

title = "High Level Antibody Avidity is Achieved in HIV-Seropositive Recipients of an Inactivated Split Adjuvanted (AS03A) Influenza Vaccine",

author = "Yam, {Karen K.} and Erica Gipson and Marina Klein and Sharon Walmsley and David Haase and Scott Halperin and David Scheifele and Ward, {Brian J.} and Curtis Cooper",

note = "Funding Information: Acknowledgments This study was funded by the Canadian Institutes of Health Research and the Public Health Agency of Canada through the PHAC/CIHR Influenza Research Network (PCIRN; CIHR grant 96974). Additional funding and logistical support was provided by the CIHR Canadian HIV Trials Network (CTN 253). Drs. Cooper and Walmsley acknowledge support as Ontario HIV Treatment Network Career Scientists. Elizabeth Allen is acknowledged for technical support. The authors declare that they have no conflict of interest. Publisher Copyright: {\textcopyright} 2014, Springer Science+Business Media New York.",

year = "2014",

month = aug,

day = "1",

doi = "10.1007/s10875-014-0054-z",

language = "English",

volume = "34",

pages = "655--662",

journal = "Journal of Clinical Immunology",

issn = "0271-9142",

publisher = "Springer New York",

number = "6",

}

TY - JOUR

T1 - High Level Antibody Avidity is Achieved in HIV-Seropositive Recipients of an Inactivated Split Adjuvanted (AS03A) Influenza Vaccine

AU - Yam, Karen K.

AU - Gipson, Erica

AU - Klein, Marina

AU - Walmsley, Sharon

AU - Haase, David

AU - Halperin, Scott

AU - Scheifele, David

AU - Ward, Brian J.

AU - Cooper, Curtis

N1 - Funding Information: Acknowledgments This study was funded by the Canadian Institutes of Health Research and the Public Health Agency of Canada through the PHAC/CIHR Influenza Research Network (PCIRN; CIHR grant 96974). Additional funding and logistical support was provided by the CIHR Canadian HIV Trials Network (CTN 253). Drs. Cooper and Walmsley acknowledge support as Ontario HIV Treatment Network Career Scientists. Elizabeth Allen is acknowledged for technical support. The authors declare that they have no conflict of interest. Publisher Copyright: © 2014, Springer Science+Business Media New York.

PY - 2014/8/1

Y1 - 2014/8/1

UR - http://www.scopus.com/inward/record.url?scp=84939885947&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84939885947&partnerID=8YFLogxK

U2 - 10.1007/s10875-014-0054-z

DO - 10.1007/s10875-014-0054-z

M3 - Article

C2 - 24824648

AN - SCOPUS:84939885947

SN - 0271-9142

VL - 34

SP - 655

EP - 662

JO - Journal of Clinical Immunology

JF - Journal of Clinical Immunology

IS - 6

ER -

High Level Antibody Avidity is Achieved in HIV-Seropositive Recipients of an Inactivated Split Adjuvanted (AS03_A) Influenza Vaccine

ASJC Scopus Subject Areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this